0.681
5.68%
-0.041
Cidara Therapeutics Inc stock is currently priced at $0.681, with a 24-hour trading volume of 358.91K.
It has seen a -5.68% decreased in the last 24 hours and a -4.65% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.729 pivot point. If it approaches the $0.6733 support level, significant changes may occur.
Cidara Therapeutics Inc Stock (CDTX) Financials Data
Cidara Therapeutics Inc (CDTX) Revenue 2024
CDTX reported a revenue (TTM) of $56.54 million for the quarter ending September 30, 2023, a -7.75% decline year-over-year.
Cidara Therapeutics Inc (CDTX) Net Income 2024
CDTX net income (TTM) was -$30.70 million for the quarter ending September 30, 2023, a +7.61% increase year-over-year.
Cidara Therapeutics Inc (CDTX) Cash Flow 2024
CDTX recorded a free cash flow (TTM) of -$31.05 million for the quarter ending September 30, 2023, a -38.07% decrease year-over-year.
Cidara Therapeutics Inc (CDTX) Earnings per Share 2024
CDTX earnings per share (TTM) was -$0.39 for the quarter ending September 30, 2023, a +29.09% growth year-over-year.
Cidara Therapeutics Inc Stock (CDTX) Latest News
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
GlobeNewswire Inc.
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Zacks Investment Research
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
GlobeNewswire Inc.
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
Zacks Investment Research
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):